KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Common Equity (2016 - 2025)

Historic Common Equity for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $789.2 million.

  • Alnylam Pharmaceuticals' Common Equity rose 107632.96% to $789.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $789.2 million, marking a year-over-year increase of 107632.96%. This contributed to the annual value of $789.2 million for FY2025, which is 107632.96% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Common Equity stood at $789.2 million, which was up 107632.96% from $233.9 million recorded in Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Common Equity peaked at $926.2 million during Q1 2021, and registered a low of -$408.1 million during Q2 2023.
  • In the last 5 years, Alnylam Pharmaceuticals' Common Equity had a median value of $91.3 million in 2024 and averaged $184.4 million.
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 33183.99% in 2023, then soared by 827055.75% in 2025.
  • Alnylam Pharmaceuticals' Common Equity (Quarter) stood at $588.2 million in 2021, then crashed by 126.9% to -$158.2 million in 2022, then tumbled by 39.45% to -$220.6 million in 2023, then soared by 130.41% to $67.1 million in 2024, then soared by 1076.33% to $789.2 million in 2025.
  • Its last three reported values are $789.2 million in Q4 2025, $233.9 million for Q3 2025, and $250.6 million during Q2 2025.